Catalyst

Slingshot members are tracking this event:

Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SGYP Community voting in process

Additional Information

Additional Relevant Details Synergy Pharmaceuticals presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body’s naturally occurring gastrointestinal (GI) peptide – uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.In vitro data presented today at DDW show that plecanatide, like uroguanylin, activates the GC-C receptor in a pH-dependent manner, and this may contribute to more frequent, well-formed bowel movements. While the under-secretion of fluid can cause constipation, the over-secretion of fluid can result in diarrhea. The balance of fluid secretion in the gut is normally achieved by a controlled – and pH-dependent – activation of the GC-C receptor by uroguanylin.
http://ir.synergypha...
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Uroguanylin, Plecanatide, Gi Peptide, Diarrhea, Fluid Balance, Constipation